TRT for Obesity-Related Low Testosterone: What a 2026 Network Meta-Analysis Found

Obesity-related functional hypogonadism describes a pattern seen in a substantial proportion of men with obesity, where excess body fat disrupts the hormonal signalling between the brain and the testes, resulting in lower testosterone levels alongside sexual dysfunction, reduced muscle mass, and often poorer blood sugar control. Unlike hypogonadism caused by a structural problem with the testes or pituitary gland, this form is considered potentially reversible, since it is driven substantially by excess weight rather than permanent organ damage, which raises an obvious clinical question: is the right first response to replace the missing testosterone directly, to treat the underlying obesity instead, or to do both.

In practice, doctors and clinics have reached for several different answers to that question: testosterone replacement therapy (TRT) on its own, TRT combined with structured lifestyle change such as diet and exercise programmes, a category of treatment aimed at restoring the body's own natural testosterone production rather than replacing it directly, and, increasingly, GLP-1 receptor agonist weight-loss medications such as those used for type 2 diabetes and obesity. Until now, no single study had compared all of these approaches against each other directly and consistently.

That gap matters in Ireland specifically, since men presenting to private clinics with low energy, reduced libido or sexual dysfunction and a confirmed low testosterone reading are often offered TRT as a first-line option, without the conversation always extending to whether the underlying cause is weight-related and, if so, whether a combined approach might serve them better than testosterone alone. A properly conducted comparison of these strategies against each other is exactly the kind of evidence needed to inform that conversation.

A team of researchers from Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital in China, published in the Journal of Sexual Medicine in August 2026, searched four major medical databases, PubMed, Embase, Web of Science and the Cochrane Library, from their earliest records through April 2026, looking for randomised controlled trials that tested any of these strategies in adult men with obesity-related functional hypogonadism. They identified 23 eligible trials covering a combined 1,899 participants.

Rather than comparing treatments only in pairs, as a conventional meta-analysis does, the team used a technique called network meta-analysis, which allows every treatment to be statistically compared against every other, even when not every pair of treatments was tested head-to-head in the same trial, by using a shared comparator such as placebo or usual care as a bridge. Every included trial's risk of bias was assessed using the Cochrane RoB 2 tool, and the certainty of every individual result was graded using CINeMA, a framework built specifically for rating confidence in network meta-analysis findings, which accounts for how consistent, how precise and how free of bias the underlying evidence actually is.

Compared with usual care or placebo, testosterone replacement therapy combined with structured lifestyle therapy produced the largest average increase in total testosterone of any strategy tested, followed by the therapy aimed at restoring the body's own testosterone production, and then testosterone replacement alone, which still produced a smaller but statistically significant rise. Testosterone plus lifestyle therapy was also the only strategy that produced a statistically significant improvement in the International Index of Erectile Function, a standard, validated questionnaire used to measure erectile function in clinical trials.

That combination result, better hormone levels and better sexual function together, is a genuinely useful finding for anyone weighing up whether to add supervised lifestyle support to a testosterone prescription rather than relying on medication alone. It does not, however, mean testosterone alone was without benefit: taken by itself, testosterone replacement therapy reduced waist circumference and increased lean muscle mass compared with placebo, which are both outcomes patients with obesity-related hypogonadism commonly hope to improve.

One of the more important results in this review is a negative one. Despite obesity-related hypogonadism being closely tied to metabolic health, none of the treatment strategies tested, including testosterone alone, testosterone with lifestyle change, the endogenous-restoration therapy, or the GLP-1 receptor agonist-based approach, produced a statistically significant reduction in glycated haemoglobin, or HbA1c, the standard blood test used to track average blood sugar control over the preceding two to three months, compared with usual care or placebo.

That is a meaningful finding to report honestly rather than to skip past. It suggests that raising testosterone, restoring natural testosterone production, or even using a weight-loss drug in the doses and durations tested across these particular trials did not reliably translate into better blood sugar control on its own, at least not by an amount these 23 trials could detect with statistical confidence. Anyone hoping that correcting low testosterone would, by itself, meaningfully improve blood sugar control should treat that hope as unproven by this evidence, rather than assume it follows automatically from the hormone or weight changes the review did find.

The review also confirmed a safety signal that is already well recognised in testosterone therapy generally: testosterone replacement therapy increased haematocrit, the proportion of red blood cells in the blood, compared with placebo. A raised haematocrit thickens the blood and is associated with an increased risk of clotting-related problems if it climbs too high, which is precisely why testosterone therapy prescribed through a doctor in Ireland requires regular blood monitoring rather than being a start-and-forget treatment.

Encouragingly, the review's authors reported no significant difference in overall adverse events between the treatment groups and placebo across the pooled trials, meaning the haematocrit increase did not translate into an detectably higher rate of the sorts of side effects tracked in these trials. That is a reassuring detail, but it does not remove the need for the monitoring haematocrit increases call for, since a well-tolerated average across a trial population does not rule out a meaningful risk for an individual patient whose haematocrit rises further than most.

The review's authors were explicit that confidence in many of the individual treatment comparisons was low or very low, using the CINeMA framework, largely because the 23 included trials differed considerably in the specific patient populations enrolled, the exact treatment protocols and doses used, and how long participants were followed up. Sensitivity analyses, which re-run the statistics while excluding certain trials to check whether the main findings hold up, and direct-evidence analyses, which look only at trials that tested a specific pair of treatments against each other rather than relying on the indirect network comparisons, generally supported the direction of the main findings, which is a point in favour of taking them seriously.

That said, a network meta-analysis of this kind is best read as the most rigorous available summary of a genuinely mixed and still-developing evidence base, rather than as a definitive final ranking. The authors themselves concluded that these findings should inform individualised treatment discussions between doctor and patient rather than dictate a single default treatment, and that longer, well-designed head-to-head trials are still needed to confirm the comparative rankings with greater certainty.

Testosterone is a prescription-only medicine in Ireland, and it is not available legally without a diagnosis from a doctor confirming genuinely low testosterone alongside relevant symptoms, followed by ongoing supervision that should include monitoring of haematocrit and other blood markers exactly because of the safety signal this review confirms. Private clinics offering TRT in Ireland vary in how thoroughly they investigate the underlying cause of low testosterone before prescribing, and this review is a useful, evidence-based reason to ask a prescribing clinic directly whether obesity-related hormonal disruption has been considered and whether structured lifestyle support is being offered alongside testosterone, rather than testosterone being presented as a stand-alone fix.

It is also a reasonable basis to ask whether a weight-focused approach, potentially including newer weight-loss medications now more widely prescribed in Ireland for obesity, has been discussed as an alternative or complement to testosterone specifically for men whose low testosterone appears to be driven by excess weight rather than a separate underlying condition. Buying testosterone without a prescription or medical supervision, from unregulated online sellers or otherwise, bypasses exactly the blood monitoring this evidence shows matters, and carries real safety risk that this review's own findings help illustrate rather than dismiss.

The Medical Council of Ireland's guidance for registered doctors requires that prescribing be based on a proper clinical assessment and ongoing review, rather than on a single blood test result taken in isolation, which is directly relevant here given how much this review's findings depend on the underlying cause of a patient's low testosterone. A private clinic that diagnoses and treats obesity-related hypogonadism as if it were a simple, direct testosterone deficiency, without addressing the weight driving it, is arguably not applying this evidence as fully as it could be, even if the prescription itself is entirely legitimate.

A 2026 network meta-analysis of 23 randomised controlled trials in obese men with functional hypogonadism found that testosterone combined with structured lifestyle change produced the strongest results for testosterone levels and erectile function, while testosterone alone still improved waist circumference and lean mass but raised haematocrit, a marker requiring monitoring. No treatment strategy tested, including testosterone and GLP-1-based weight-loss drugs, significantly improved blood sugar control, and the authors rated confidence in most of the specific comparisons as low to very low pending further, more definitive trials.

The honest reading of this evidence is not that any one treatment has been proven superior, but that a combined approach, addressing both the hormonal and the underlying weight-related drivers of the condition under proper medical supervision, currently has the strongest support across the outcomes that matter most to patients, while testosterone taken in isolation still carries a real, monitorable safety consideration that any legitimate Irish prescriber should be actively managing.